Navigation Links
John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
Date:12/7/2010

latrexate Effective in Patients with T-cell Lymphoma who Fail ICE-Based Regimens? (Abstract number #1753; poster session, December 4, 5:30-7:30 p.m.)

Andre Goy, M.D., M.S., Deputy Director and Chief, Lymphoma and Director, Clinical and Translational Cancer Research, John Theurer Cancer Center, and colleagues analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) which led to the FDA approval of pralatrexate in September 2009.

The goal of the study was to determine the outcome of the subset of patients with Peripheral T-Cell Lymphoma (PTCL) who had previously received and failed or relapsed after ICE chemotherapy. ICE is a combination of ifosfamide, carboplatin and etoposide, currently used as standard salvage therapy in patients with PTCL in preparation of high dose therapy followed by autologous stem cell transplantation.

PTCL is an especially aggressive cancer that attacks immune cells that protect the body from viruses. It is typically resistant to second-line treatments, such as ICE regimens.

Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.

"Given the results, we will continue to explore the role of pralatrexate in combination with other agents to build upon its single agent activity. Our investigation will include PTCL patients in relapse and in the frontline setting in an effort to improve outcomes," said Dr. Goy.

Response of Multiple Myeloma Patients to Carfilzomib After Other Treatments Have Failed (Abstract number 985; oral session, December 7, 7:30 a.m.)

A new proteasome inhibitor may hold hope for patients with multiple myeloma who have been treated unsuccessfully with other drugs. Dr. Siegel and colleagues conducted an open-label single-arm phase 2b study of carfilzomi
'/>"/>

Contact: Amy Leahing
amy.leahing@gmail.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related medicine news :

1. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
2. John Theurer Cancer Center to present innovative research at 2 surgical meetings
3. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
4. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
5. The John Theurer Cancer Center recognizes medical physics team for safety track record
6. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
7. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
8. John Theurer Cancer Center offers breakthrough radiation measurement technology
9. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
10. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
11. Daily Aspirin Linked to Steep Drop in Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... The ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction ... (AAN). The FSHD care guideline is published today. , This new guideline ...
(Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just ... “The patient is high-end athlete, whose accomplishments include running in 27 triathlons and ... tendon pain, which was diagnosed as tendinitis. I did an ultrasound and found ...
(Date:7/27/2015)... ... 27, 2015 , ... David Gilmour has added additional tour dates ... additional night at each of his original four tour stops in the United States ... Gilmour’s 2016 North America tour dates: , Thursday, March 24, 2016 (3/24/16) at the ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program in ... support its mission of reducing the number of deaths and injuries occurring from police ... their families. PursuitSAFETY works with the police to find better and safer ways ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth loss ... incur a lot of stress, pain, discomfort and embarrassment, which is why they are ... reaps the benefits of implants with the cost savings of dentures for anyone on ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4
... higher levels of a fatty acid known as docosahexaenoic ... lower risk //of developing dementia and Alzheimer’s disease, according ... genetic factors have all been found to increase the ... that causes 70 percent of cases of dementia in ...
... research article published in the Lancet has brought to light ... the Indian //community. With only 2.2percent of the Adult population ... shows that the Indian body constitution is responsible. ... in India between the age groups of 30 and 50 ...
... debilitating neurological disorder called Guillain-Barre syndrome in rare cases// ... these findings should not make people shy away from ... study by the Institute for Clinical Evaluative Sciences (ICES), ... referring to the risk of Guillain-Barre syndrome (GBS). He ...
... improve the use of continuous positive airway pressure// (CPAP) ... study published in the November issue of CHEST, the ... (ACCP), finds that patients with OSA who were given ... their CPAP machines than patients with OSA taking a ...
... weight-loss surgery, obesity surgery and gastric-bypass surgery. In- hospital ... The mortality rate as per records is 2 per ... company, conducted a study on bariatric surgery complication rates ... in hospitals in accordance with their ratings. ...
... that lead to dehydration can signal a future attack for ... American// College of Rheumatology Annual Scientific Meeting in Washington DC. ... causes severe pain and swelling of the joints. The attacks, ... few days, most often the big toe, can also generate ...
Cached Medicine News:Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Rare Neurological Disorder Linked to Flu shot 2Health News:Research Questions Use of Sleep Meds for Patients with Apnea 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 3Health News:It's the Heat and the Humidity: How Each Worsens Gout Symptoms 2
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology ... announces a strategic cooperation with the South Korean BioTech ... a joint venture Medybloom to develop and promote Type ... China . Medytox, the Botulinum ... and is also the fourth company in the world ...
(Date:7/27/2015)... , July 27, 2015   DocResponse ... technology application in a peer-reviewed study , ... triage: audit study", published in the July issue ... study by Harvard Medical School researchers determined that ... DocResponse listing the correct diagnosis first in standardized ...
(Date:7/27/2015)... , Belgium , July 27, ... VNRX), a life sciences company focused on developing blood-based ... and other conditions, today announced that it has engaged ... organization, Global Specimen Solutions, Inc. (GSS), to support initial ... cancer tests. Under the agreement, GSS ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7
... CVM ) announces that its CEL-1000 immunomodulator was ... against the recombinant hepatitis B,virus protein more quickly than ... was seen within 14 days, most pronounced with a ... up to a 40% increase in antibody,signal at day ...
... Ontario, Sept. 19 ArtJen Complexus Holdings,Corp. (http://www.fbcx.com ... trial with obese type 2 diabetics and an animal ... studied by a major US,west-coast university medical center. The ... fiber that binds dietary fat will involve,overweight but not ...
Cached Medicine Technology:CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein 2CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein 3ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx 2
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Plus cylinders only trial lens set....
Magnets move the color disks, Protects Disks from fingerprints, Keeps all the disks in one place, Clear glass insures accurate color perception, Makes Color testing fun....
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: